A MULTICENTRE STUDY OF ASSESSING THE EFFECTIVENESS OF SALVAGING LYMPHADENECTOMY IN PATIENTS WITH PROSTATE CANCER WITH DISEASE PROGRESSION AFTER THE RADICAL TREATMENT

Prostate cancer (PC) is one of the most urgent problems of modern oncourology because of the continuing high incidence of this pathology. The main methods of radical treatment of patients with localized and locally advanced prostate cancer are radical prostatectomy (RP) and radiotherapy – remote (RRT) or brachytherapy.  However, the frequency of biochemical markers of disease progression after curative treatment is high and reaches up to 27–53%. It is extremely important to find the tumor lesion that leads to the increase of the marker. The  palliative hormone therapy (PHT) was the only accepted method in patients with occurrence of distant metastases in recent time. However, a significant number of patients relapse marker may be associated with the so-called oligo-metastatic disease progression, in which the number of detected metastatic lesions is minimal. As the results of the research, the use of surgical or radiological treatment in selected patients of this cohort can significantly increase the length of time prior to the appointment of HT, and in some cases completely abandon its holding.

Purpose. To evaluate the results of the saving pelvic lymphadenectomy in patients with prostate cancer with disease progression after radical therapies.

Patients and methods. The article summarizes the results of surgical treatment of patients who have undergone life-saving lymphadenectomy about oligo-nodal metastatic progression of prostate cancer after treatment in 3 centers – P. Hertsen MORI, the branch of NMRRC; N. Petrov Research Institute of Oncology and Russian scientific center of radiology and surgical technologies. In this multicenter study they evaluated the immediate and remote results of surgical treatment of 57 patients.

Results. The results performed the high efficiency of the method of the saving pelvic lymphadenectomy in patients with prostate cancer with disease progression after radical treatment. So, response to therapy and reduction in the marker level was observed in 47 (82.5%) patients. The decline in PSA level ≥50% from initial level in a month after the operation was in 38 (66,7%) patients. A complete answer in the form of lower marker ≤0.2 ng/ml was observed in 13 (22,8%) patients. For the entire median follow-up period of 12 months, patients with complete response to therapy had received any hormonal treatment.

Conclusion. The saving pelvic lymphadenectomy is an effective method for the treatment of patients with the presence of lymphogenic progression of prostate cancer after a radical treatment with satisfactory oncological results. A significant contingent of patients, SLE is associated with good response to therapy and reduction in PSA levels and long disease-free period. In some patients the removal of nodal metastases allows to postpone or to abandon the HT and hope to increase overall survival of patients.

1. Zlokachestvennye novoobrazovaniya v Rossii v 2014 g [Malignant neoplasms in Russia in 2014]. Ed by Kaprin A. D., Starinskii V. V., Petrova G. V. Мoscow, 2016. (In Russian). Available at: http://www.oncology.ru/service/statistics/malignant_tu-mors/2014.pdf. Accessed 17.09.2016. (In Russian).

2. Han M., Partin A. W., Pound C. R., Epstein J. I., Walsh P. C. Long-term biochem- ical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the15-year Johns Hopkins experience. UrolClin North Am. 2001; 28: 555–565.

3. Simmons M. N., Stephenson A. J., Klein E. A. Natural history of biochemical recur- rence after radical prostatectomy: risk assessment for secondary therapy. EurUrol. 2007; 51: 1175–1184. DOI: http://dx.doi.org/10.1016/j.eururo.2007.01.015

4. Suardi N., Porter C. R., Reuther A. M., Walz J., Kodama K., Gibbons R. P., et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer. 2008; 112: 1254–1263. DOI: http://dx.doi.org/10.1002/cncr.23293

5. Roehl K. A., Han M., Ramos C. G., Antenor J. A., Catalona W. J. Cancer progres- sion and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004; 172: 910–914. DOI: http://dx.doi.org/10.1097/01.ju.0000134888.22332.bb

6. Pound C. R., Partin A. W., Eisenberger M. A., Chan D. W., Pearson J. D., Walsh P. C. Natural history of progression after PSA elevation following radi- cal prostatectomy. JAMA. 1999 May; 281 (17): 1591–1597. DOI: http://dx.doi.org/10.1001/jama.281.17.1591

7. Schweizer M. T., Zhou X. C., Wang H., Yang T., Shaukat F., Partin A. W., et al. Me- tastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol. 2013; 24 (11): 2881–2886. DOI: http://dx.doi.org/10.1093/annonc/mdt335

8. Garcia J. R., Morenco C., Valls F., Cozar P., Bassa P., Soler M., et al. Diagnostic performance of bone scintigraphy and 11C–Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer. Rev Esp Med Nucl Imagen Mol. 2015 May-Jun; 34 (3): 155–161. DOI: http://dx.doi.org/10.1016/j.remn.2014.08.001

9. Von Eyben F. E., Kairemo K. Metaanalysis of 11C-holine and 18F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun. 2014; 35 (3): 221–230. DOI: http://dx.doi.org/10.1097/mnm.0000000000000040

10. Afshar-Oromieh A., Zechmann C. M., Malcher A., Eder M., Eisenhut M., Lin- hart H. G., et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Jan; 41 (1): 11–20. 10.1007/s00259–013–2525–5. DOI: http://dx.doi.org/10.1007/s00259–013–2525–5

11. Vlasova O. P., German K. E., Krilov V. V., Petriev V. M., Epstein N. B. New Ra- diopharmaceuticals Based on Prostate-Specific Inhibitors of Membrane Antigen for Diagnostics and Therapy of Metastatic Prostate Cancer. Vestnik Rossiiskoi akademii meditsinskikh nauk (Annals of the Russian academy of medical sciences). 2015; 70 (3): 360–366. DOI: http://dx.doi.org/10.15690/vramn.v70i3.1334 (In Russian).

12. Eiber M., Maurer T., Souvatzoglou M., Beer A. J., Ruffani A., Haller B., et al. Eval- uation of Hybrid Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recur- rence After Radical Prostatectomy. J Nucl Med. 2015 May; 56 (5): 668–674. DOI: http://dx.doi.org/10.2967/jnumed.115.154153

13. Osborne J. R., Akhtar N. H., Vallabhajosula S., Anand A., Deh K., Tagawa S. T. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013 Feb; 31 (2): 144–154. DOI: http://dx.doi.org/10.1016/j.urolonc.2012.04.016

14. Rigatti P., Suardi N., Briganti A., Da Pozzo L. F., Tutolo M., Villa L., et al. Pelvic/ret- roperitoneal salvage lymph node dissection for patients treated with radical prostatec- tomy with biochemical recurrence and nodal recurrence detected by [11C]choline pos- itron emission tomography/computed tomog-raphy. Eur Urol. 2011; 60 (5): 935–943. DOI: http://dx.doi.org/10.1016/j.eururo.2011.07.060

15. Jilg C. A., Rischke H. C., Reske S. N., Henne K., Grosu A. L., Weber W., et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate can- cer. J Urol. 2012; 188 (6): 2190–2197. DOI: http://dx.doi.org/10.1016/j.juro.2012.08.041

16. Tilki D., Mandel P., Seeliger F., Kretschmer A., Karl A., Ergün S., et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical pros- tatectomy. J Urol. 2015 Feb; 193 (2): 484–490. DOI: http://dx.doi.org/10.1016/j.juro.2014.08.096

17. Winter A., Henke R. P., Wawroschek F. Targeted salvage lymphadenectomy in patients treated with radical prostatectomy with biochemical recurrence: complete bio- chemical response without adjuvant therapy in patients with low volume lymph node recurrence over a long-term follow-up. BMC Urol. 2015 Feb 21; 15: 10. DOI: http://dx-.doi.org/10.1186/s12894–015–0004-y

18. Suardi N., Karnes J., Joniau S., et al. Salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and imaging-detected nodal metastases. J Urol. 2013; 189: e317–318.

19. Suardi N., Gandaglia G., Gallina A., Di Trapani E., Scattoni V., Vizziello D., et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow up of 5 years. Eur Urol. 2015 Feb; 67 (2): 299–309. DOI: http://dx.doi.org/10.1016/j.eururo.2014.02.011